AstraZeneca Nolvadex Black Box Added For Breast Cancer Risk Reduction Use
Executive Summary
AstraZeneca's Nolvadex black box warns of uterine malignancies, stroke and pulmonary embolism associated with use of the oncologic to reduce the risk of breast cancer, revised labeling says
You may also be interested in...
Lilly Evista Breast Cancer Market May Build On Osteo Acceptance
Physician experience in treating osteoporosis patients with Lilly's Evista (raloxifene) might improve the product's uptake for reducing the risk of breast cancer
Lilly Evista Breast Cancer Market May Build On Osteo Acceptance
Physician experience in treating osteoporosis patients with Lilly's Evista (raloxifene) might improve the product's uptake for reducing the risk of breast cancer
Cancer Consumer Groups Oppose Oncologic Surrogates Citing WHI Experience
The Women's Health Initiative experience suggests that surrogate endpoints should not be used in oncology, several cancer and consumer advocacy organizations state in a letter to FDA Commissioner McClellan